Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Finished

UNBIAS Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation.

Coordinator
Universitatsklinikum Bonn, Germany
Runs
1 August 2023 to 31 January 2025
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101123144

What the project is doing

In the project's own words, from its summary on CORDIS.

With a growing ageing population, there is an imminent demand to develop new therapeutic strategies to ameliorate disorders of the hematopoietic system. Our innate immune system can remember its previous encounters with inflammatory triggers. Epigenetic memories of previous inflammatory experiences throughout an individual's lifetime are imprinted in hematopoietic stem cells (HSCs), a small pool of bone marrow progenitors that give rise to all our blood cells.

Inflammation harms HSCs causing their functional decline and premature ageing. It also causes long-term differentiation bias, and a heightened basal inflammatory status, known as “inlfammageing”. The most striking characteristic of aged HSCs is their increased expression of platelet and megakaryocyte markers and their commitment towards platelet biogenesis, referred to as “Platelet-bias."" Platelet bias has important consequences to human health.

In our ERC starting grant project PLAT-IL-1 (714175), we discovered that platelets boost the inflammatory capacity of innate immune cells and are essential for the cytokine production of human monocytes. Our findings support that a dangerous combination of myeloid and platelet bias in inflammation-exposed HSCst results in a heightened innate immune activation. The injuries to HSCs are persistent and continue even after the clearance of the inflammatory insult, indicating that remnants of inflammatory events accrue and prolong damage to HSCs.

Hence, if we could “erase"" these harmful remnants, we could UNBIAS HSCs differentiation and prevent hyper-inflammation. In our ERC-funded project, we developed novel nanobodies that efficiently eliminate remnants of inflammation in vivo. In this PoC project, we will test the ability of nanobodies to erase memories from previous inflammatory events and prevent hyper-inflammation. This project will be a stepping stone to licensing our nanobodies to industrial partners.""

Who is involved

OrganisationCityCountryRole
Universitatsklinikum BonnBonnGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI